Aamodt WW, Waligorska T, Shen J, Tropea TF, Siderowf A, Weintraub D, Grossman M, Irwin D, Wolk DA, Xie SX, Trojanowski JQ, Shaw LM, Chen-Plotkin AS (2021) Neurofilament light chain as a biomarker for cognitive decline in parkinson disease. Mov Disord 36:2945–2950

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arai H, Schmidt ML, Lee VM, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ (1992) Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson’s disease. Neurology 42:1315–1322

Article  CAS  PubMed  Google Scholar 

Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91:56–66

Article  CAS  PubMed  Google Scholar 

Backstrom D, Granasen G, Domellof ME, Linder J, Jakobson Mo S, Riklund K, Zetterberg H, Blennow K, Forsgren L (2018) Early predictors of mortality in parkinsonism and Parkinson disease: a population-based study. Neurology 91:e2045–e2056

Article  PubMed  PubMed Central  Google Scholar 

Backstrom DC, Eriksson Domellof M, Linder J, Olsson B, Ohrfelt A, Trupp M, Zetterberg H, Blennow K, Forsgren L (2015) Cerebrospinal fluid patterns and the risk of future dementia in early, incident parkinson disease. JAMA Neurol 72:1175–1182

Article  PubMed  Google Scholar 

Cochrane CJ, Ebmeier KP (2013) Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology 80:857–864

Article  PubMed  PubMed Central  Google Scholar 

Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB (2017) Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain 140:1959–1976

Article  PubMed  Google Scholar 

Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, Toffanin E, Cagnin A, Briani C, Pegoraro E, Soraru G (2017) Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol 74:525–532

Article  PubMed  PubMed Central  Google Scholar 

Halliday G, Hely M, Reid W, Morris J (2008) The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 115:409–415

Article  PubMed  Google Scholar 

Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55

Article  CAS  PubMed  Google Scholar 

Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K, Fs SB (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88:930–937

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442

Article  CAS  PubMed  Google Scholar 

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577–589

Article  CAS  PubMed  Google Scholar 

Lin CH, Li CH, Yang KC, Lin FJ, Wu CC, Chieh JJ, Chiu MJ (2019) Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 93:e1104–e1111

Article  CAS  PubMed  Google Scholar 

Macleod AD, Taylor KS, Counsell CE (2014) Mortality in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 29:1615–1622

Article  PubMed  Google Scholar 

Moberg PJ, Lazarus LW, Mesholam RI, Bilker W, Chuy IL, Neyman I, Markvart V (2001) Comparison of the standard and structured interview guide for the Hamilton depression rating scale in depressed geriatric inpatients. Am J Geriatr Psychiatry 9:35–40

Article  CAS  PubMed  Google Scholar 

Mollenhauer B, Dakna M, Kruse N, Galasko D, Foroud T, Zetterberg H, Schade S, Gera RG, Wang W, Gao F, Frasier M, Chahine LM, Coffey CS, Singleton AB, Simuni T, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Marek K, Siderowf A, Cedarbaum JM, Hutten SJ, Trenkwalder C, Graham D (2020) Validation of Serum neurofilament light chain as a biomarker of Parkinson’s disease progression. Mov Disord 35:1999–2008

Article  CAS  PubMed  PubMed Central  Google Scholar 

Movement Disorder Society Task Force on Rating Scales for Parkinson’s D (2003) The Unified Parkinson’s disease rating scale (UPDRS): status and recommendations. Mov Disord 18:738–750

Article  Google Scholar 

Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699

Article  PubMed  Google Scholar 

Ng ASL, Tan YJ, Yong ACW, Saffari SE, Lu Z, Ng EY, Ng SYE, Chia NSY, Choi X, Heng D, Neo S, Xu Z, Keong NCH, Tay KY, Au WL, Tan LCS, Tan EK (2020) Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease. Mol Neurodegener 15:33

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oosterveld LP, Verberk IMW, Majbour NK, El-Agnaf OM, Weinstein HC, Berendse HW, Teunissen CE, van de Berg WDJ (2020) CSF or serum neurofilament light added to alpha-Synuclein panel discriminates Parkinson’s from controls. Mov Disord 35:288–295

Article  CAS  PubMed  Google Scholar 

Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El-Agnaf O, Mollenhauer B, Blennow K, Calabresi P (2019) CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol 18:573–586

Article  CAS  PubMed  Google Scholar 

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601

Article  PubMed  Google Scholar 

Schapira AHV, Chaudhuri KR, Jenner P (2017) Erratum: Non-motor features of Parkinson disease. Nat Rev Neurosci 18:509–509

Article  CAS  PubMed  Google Scholar 

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653

Article  PubMed  Google Scholar 

Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, Druyeh R, Malone IB, Ahsan RL, Pemberton H, Klimova J, Mead S, Blennow K, Rossor MN, Schott JM, Zetterberg H, Fox NC (2017) Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology 89:2167–2175

Article  PubMed  PubMed Central  Google Scholar 

Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA (2013) The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 84:1258–1264

Article  PubMed  Google Scholar 

Ye R, Locascio JJ, Goodheart AE, Quan M, Zhang B, Gomperts SN (2021) Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson’s disease: an 8-year longitudinal study. Parkinsonism Relat Disord 85:11–16

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ygland Rodstrom E, Mattsson-Carlgren N, Janelidze S, Hansson O, Puschmann A (2022) Serum neurofilament light chain as a marker of progression in Parkinson’s disease: long-term observation and implications of clinical subtypes. J Parkinsons Dis 12:571–584

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Cao B, Hou Y, Gu X, Wei Q, Ou R, Zhao B, Luo C, Shang H (2022) Neurofilament light chain predicts disease severity and progression in multiple system atrophy. Mov Disord 37:421–426

Article  CAS  PubMed  Google Scholar